# Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07150663/  
OnCo record `nct07150663` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Megestrol acetate in non-small-cell lung cancer, run by Changchun GeneScience Pharmaceutical Co., Ltd., now recruiting.

## Summary

Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07150663 by Changchun GeneScience Pharmaceutical Co., Ltd., with 134 participants planned, started 2025-08-20 and due to reach its primary completion in 2027-06-30. Interventions recorded: Nano-crystalline Megestrol Acetate Oral Suspension.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07150663
- Phase: 3
- Setting: A Prospective, Randomized, Parallel-Controlled Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
- Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
- Enrolled: 134

## Sources

- ClinicalTrials.gov NCT07150663: https://clinicaltrials.gov/study/NCT07150663

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Megestrol acetate](https://onco.cc/drugs/megestrol/)
- companies: [Changchun GeneScience Pharmaceutical](https://onco.cc/companies/changchun-genescience/)

---
JSON: https://onco.cc/api/v1/entities/nct07150663.json